Simpledeep Banipal, MD
Vascular Surgery · Riverside, CANPI 1306181375
Payments from drug & device makers
Across 54 payments — averaging $72.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Silk Road Medical, Inc.$441
- Terumo Medical Corporation$383
- W. L. Gore & Associates, Inc.$357
- Bard Peripheral Vascular, Inc.$285
- Bolton Medical Inc$148
- plus $229 from 6 others
What the payments were for
- Travel & lodging$1,11728%
- Food & beverage$2,82472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 25 | $2,096 |
| Silk Road Medical, Inc. | 6 | $441 |
| Terumo Medical Corporation | 4 | $383 |
| W. L. Gore & Associates, Inc. | 6 | $357 |
| Bard Peripheral Vascular, Inc. | 2 | $285 |
| Bolton Medical Inc | 1 | $148 |
| Getinge USA Sales, LLC | 3 | $63 |
| Cook Medical LLC | 1 | $53 |
| Tactile Systems Technology Inc | 2 | $39 |
| Smith+Nephew | 2 | $36 |
| Cagent Vascular Inc | 1 | $21 |
| Boston Scientific | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Valiant Captivia$761
- ENROUTE Transcarotid Neuroprotection System$369
- Endurant$304
- ENROUTE Transcarotid Stent$184
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$184
- EXCLUDER AAA Endoprosthesis$157
- Azur CX Detachable$156
- RELAY THORACIC STENT-GRAFT WITH PLUS DELIVERY SYSTEM$148
- C3 Delivery System$144
- ENDURANT IIS$104
How this compares
$3,940 in reported general payments places this provider in the 45th percentile of 519 vascular surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PradaxaDabigatran Etexilate Mesylate | 29 | $5,322 |
| ClopidogrelClopidogrel Bisulfate | 51 | $934 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 23 | $777 |
| Gabapentin | 65 | $767 |
| Atorvastatin Calcium | 40 | $462 |
| Pregabalin | 15 | $291 |
| Tramadol Hcl | 37 | $233 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Riverside
- Venita ChandraPalo Alto$947K
- Leigh Ann ObanionFresno$932K
- Sukgu HanLos Angeles$765K
- Mahmoud Malasla Jolla$508K
- Son DuongFountain Valley$503K
- Leo FongClovis$496K
- Jason LeePalo Alto$403K
- Bernardo Curi MendesLos Angeles$376K
- Trevor DerderianRancho Mirage$359K
- Karthikeshwar KasirajanPalo Alto$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.